Impact of the number of lymph nodes sampled on outcome in ypT0N0 esophageal squamous cell carcinoma patients

Journal of Surgical Oncology

Volumn 106, Issue 4, 2012, Pages 436-440

  Chao, Yin Kai ^a,c   Liu, Hui Ping ^b   Hsieh, Ming Ju ^a,c   Wu, Yi Cheng ^a,c   Liu, Yun Hen ^a,c   Yeh, Chi Hsiao ^a,c   Chang, Hsien Kun ^a,c   Tseng, Chen Kan ^a,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b BenQ Medical Center   (China)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

chemoradiotherapy; esophageal cancer; lymph node dissection; pathological complete response

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 85027934268     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23103     Document Type: Article

References (19)

1. Edge SB, Byrd DR, Compton CC, et al.: AJCC cancer staging manual. 7th edition. New York, NY: Spring-Verlag; 2010.
2. Yang HX, Xu Y, Fu JH, et al.: An evaluation of the number of lymph nodes examined and survival for node-negative esophageal carcinoma: Data from China. Ann Surg Oncol 2010; 17: 1901-1911.
3. Lin CS, Chang SC, Wei YH, et al.: Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2009; 87: 1056-1065.
4. Rizk NP, Ishwaran H, Rice TW, et al.: Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010; 251: 46-50.
5. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-234. (Pubitemid 46291702)
6. Chao YK, Chan SC, Liu YH, et al.: Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Ann Surg 2009; 249: 392-396.
7. Reynolds JV, Muldoon C, Hollywood D, et al.: Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007; 245: 707-716. (Pubitemid 46684100)
8. Kim MK, Kim SB, Ahn JH, et al.: Treatment Outcome and Recursive Partitioning Analysis-Based Prognostic Factors in Patients with Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008. 71: 725-734.
9. Rohatgi PR, Swisher SG, Correa AM, et al.: Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005; 104: 1349-1355. (Pubitemid 41356149)
10. Berger AC, Farma J, Scott WJ, et al.: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337. (Pubitemid 46207006)
11. Law S, Kwong DL, Kwok KF, et al.: Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg 2003; 238: 339-347; discussion 347-348.
12. Rohatgi PR, Swisher SG, Correa AM, et al.: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006; 106: 552-558. (Pubitemid 43157617)
13. Herrera LJ:, Extent of lymphadenectomy in esophageal cancer: How many lymph nodes is enough ? Ann Surg Oncol 2010; 17: 676-678.
14. Greenstein AJ, Litle VR, Swanson SJ, et al.: Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008; 112: 1239-1246. (Pubitemid 351429738)
15. Groth SS, Virnig BA, Whitson BA, et al.: Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg 2010; 139: 612-620.
16. Doll D, Gertler R, Maak M, et al.: Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance. World J Surg 2009; 33: 340-347.
17. Baxter NN, Morris AM, Rothenberger DA, et al.: Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: A population-based analysis. Int J Radiat Oncol Biol Phys 2005; 61: 426-431. (Pubitemid 40164437)
18. Habr-Gama A, Perez RO, Proscurshim I, et al.: Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: What does it mean ? Dis Colon Rectum 2008; 51: 277-283.
19. Solomon N, Zhuge Y, Cheung M, et al.: The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma. Ann Surg Oncol 2010; 17: 791-803.